Related Experiment Video
Updated: May 10, 2025
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
Comprehensive analysis of mRNA expression of Piezo1 and Piezo2 in tumor samples and their prognostic implications in
Tong Liang1,2, Junhong Wang3,4, Zhong Yang5
1The First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, Gansu, China. liangt21@lzu.edu.cn.
Background:
This study aims to investigate the expression pattern and clinical significance of Piezo1 and Piezo2 in various cancers, focusing on gastric cancer (GC).
Methods:
The study investigated the mRNA expression levels of Piezo1 and Piezo2 in tumor samples from different cancers using the BEST online database. The case-control studies about the relation between Piezo1 and Piezo2 and GC were retrieved from PubMed, Embase, Web of Science, and Cochrane Library. The retrieval time was from inception to October, 2023. The meta-analysis of the included literatures was conducted by the STATA 12.0 software. Additionally, the expression profiles of Piezo1 and Piezo2 in tumor and normal gastric tissues were analyzed, and their clinical drug relevance was assessed using the CPADS database. The research program has been registered with PROSPERO (CRD42023495836).
Results:
The analysis demonstrated elevated mRNA expression of both Piezo1 and Piezo2 in the majority of tumor samples. Of particular note was the significant increase observed in GC tissue compared to normal tissue (all p < 0.05). Additionally, the meta-analysis revealed a meaningful correlation between high expression levels of Piezo1 and Piezo2 and poor prognosis in patients with GC (HR = 1.48, 95% CI = 1.27-1.69, p < 0.0001). This study identified a significant correlation between high levels of Piezo1 expression and the TNM phase (OR = 1.87, 95% CI = 1.21-2.91, p = 0.005). Furthermore, enhanced Piezo2 expression was observed to be positively correlated with survival status (OR = 2.12, 95% CI = 1.31-3.44, p = 0.002). Piezo1 (p = 0.028, R2 = 0.12) and Piezo2 (p = 0.049, R2 = 0.09) have been identified as potential therapeutic targets for GC treatment, according to drug sensitivity analyses.
Conclusion:
The findings of this study indicate that the expression levels of Piezo1 and Piezo2 have the potential to serve as diagnostic indicators or therapeutic targets for GC management.
Trial Registration:
CRD42023495836 (PROSPERO).
